Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.

ABSTRACT:

Objective

To review published clinical studies on the efficacy and safety of new insulin glargine 300 units/mL (Gla-300), a new long-acting insulin analog, for the treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM).

Materials and methods

Data sources comprised primary research articles on Gla-300, including pharmacodynamic, pharmacokinetic, and clinical studies.

Results

In pharmacodynamic and pharmacokinetic studies, Gla-300 showed a flatter time-action profile and longer duration of action than Gla-100. Noninferiority of Gla-300 versus Gla-100 for lowering of glycated hemoglobin was demonstrated in Phase III clinical studies covering a range of T1DM and T2DM patient populations. Over 6-12 months of follow-up, Gla-300 consistently showed comparable glycemic

SUBMITTER: Lau IT 

PROVIDER: S-EPMC5501629 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature